Arch Therapeutics (OTCMKTS:ARTH) has been given a $3.00 target price by analysts at HC Wainwright in a research report issued on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock.
A number of other equities research analysts also recently weighed in on the company. Roth Capital reaffirmed a “buy” rating on shares of Arch Therapeutics in a research note on Tuesday, April 17th. Zacks Investment Research downgraded Arch Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 19th. Finally, Ifs Securities downgraded Arch Therapeutics from a “strong-buy” rating to an “outperform” rating in a research note on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $1.75.
ARTH opened at $0.49 on Tuesday. Arch Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $0.89.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.